BioStock: New results confirmation for Arcede Pharma

Report this content

Preclinical studies at the Università degli studi di Roma Tor Vergata confirm that the drug candidate RCD405 has both airway dilation and anti-inflammatory effects. Thus, another piece is added to the development puzzle for the Lund-based company, which is aiming for the ever-growing COPD and asthma markets.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/05/new-results-confirmation-for-arcede-pharma/

This is a press release from BioStock - Connecting Innovation & Capitalhttps://www.biostock.se

Subscribe

Documents & Links

Quick facts

BioStock: New results confirmation for Arcede Pharma
Tweet this